GLP-1 Medicaid Coverage by State: 2026 Tracker

By Kaden Coziar, Founder & Managing Editor · The RX Index Research

Does Medicaid cover GLP-1s for weight loss? Some state programs cover them with prior authorization; others exclude obesity-only use. Use the table below to check the policy evidence for your state, announced changes and public BALANCE status. Coverage for diabetes or another indication is a separate question, and a preferred-drug listing alone does not establish obesity coverage.

Find your state · Download CSV · Cite this dataset

Current Medicaid GLP-1 policy by state

State findings and public BALANCE status

The table includes all 50 states; the District of Columbia appears separately. Each row distinguishes obesity-policy findings from public BALANCE status and gives its primary source, program scope, verification date and limits. “Not verified” is not “No,” and an announcement or recommendation is not an operational benefit.

On smaller screens, scroll horizontally within the table to view all seven columns.

On smaller screens, scroll horizontally within the table to view all seven columns.

Release 2026-09-28-review-1: CSV · JSON and source records. This is not a complete current national coverage census.

What this data shows — and what it doesn’t

This tracker separates adult obesity-only coverage from coverage for other indications and distinguishes a historical national snapshot from newer state-policy observations. It does not measure approvals or guarantee coverage for an individual prescription. Product, formulation, program, prior authorization, medical-necessity rules, and the member’s circumstances all matter.

Coverage rules are not prescription-volume measures. For state-level Medicaid GLP-1 prescription counts and rates, see GLP-1 Usage by State.

The page keeps three distinctions visible: the reason for treatment, the drug and formulation, and who controls the pharmacy benefit. Fee-for-service and managed-care arrangements may follow different rules, but a managed-care card does not by itself mean the plan controls a separate drug list. A preferred-drug listing is not proof that a prescription for a particular indication will be approved.

How we built this tracker

We review state Medicaid bulletins, regulations, pharmacy manuals and indication-specific authorization criteria. National surveys supply dated historical context; they do not substitute for current state evidence.

For each record we keep current-policy findings separate from public BALANCE records. An announcement, application, recommendation or evaluation is not the same as an executed model agreement or an operational benefit. A preferred-drug listing alone is not proof that the drug is covered for obesity.

The table’s review date is the date the cited statement was checked, not its original effective date and not confirmation of every formulation or managed-care plan. When a policy, implementation date or source version cannot be established, the record says so. “Not verified” never means “No.”

The September 28 release includes all 50 states and D.C., but is not a fully resolved current national coverage census. Some findings are limited to named products or one delivery system, and some official documents have unresolved version or adoption questions. Read those limits with the finding.

Past releases remain available at their original versioned data URLs. Corrections create a new release; they do not silently rewrite an older dataset.

Download the data dictionary and methodology.

Which states cover GLP-1 medications for weight loss through Medicaid?

The July 10, 2026 historical snapshot listed Delaware, Kansas, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Rhode Island, Tennessee, Virginia, Wisconsin. This is not a September count. The table above shows newer findings only where a source was reviewed and includes its product scope, effective date when established, and verification limits.

A state’s absence from that historical roster is not a new finding about its current coverage. Check the applicable state policy and managed-care rules for the exact drug, formulation, indication, and member.

Among the reviewed findings, North Carolina’s reinstatement includes Saxenda, Wegovy and Zepbound. Massachusetts’ corrected notice ended obesity-only coverage on July 3, 2026. Utah’s May bulletin ended fee-for-service weight-loss GLP-1 coverage effective June 30, 2026. Rhode Island’s October 1 exclusion is still scheduled as of this September 28 review. Indiana has announced BALANCE participation, but an operational expansion is not verified. See each state row for the source and program scope.

Diabetes vs. weight loss: why the same drug is covered for one and not the other

The same molecule can be considered under different coverage rules depending on the prescribed product and reason for treatment. Medicaid outpatient-drug rules generally cover participating manufacturers’ drugs for non-excluded medically accepted uses, subject to permitted authorization and formulary rules. A medically accepted indication is not limited to an FDA-approved indication alone; federal law also recognizes specified compendial support. States may exclude drugs when used for weight loss, and a diagnosis does not guarantee approval of a particular product or formulation.

FDA labeling identifies the uses and populations for each product, but it does not establish a nationwide state Medicaid benefit. Check the policy for the exact drug, formulation, indication, program, and authorization rules.

Sources: FDA Foundayo approval announcement; Wegovy prescribing information; Ozempic tablets/Rybelsus prescribing information; Ozempic injection prescribing information; Social Security Act § 1927. This summary is not a substitute for the current label or state policy.

The practical upshot is that a diagnosis, FDA label, or preferred listing is not enough to determine payment. A plan or agency evaluates the requested product, formulation, indication, and applicable authorization rules.

EPSDT: Members under 21, including ages 18–20, may have an individualized medically necessary treatment pathway through EPSDT, including in states that exclude the adult benefit. That is not a guarantee that every drug, formulation, or request will be approved. See the Medicaid EPSDT overview.

Why Medicaid GLP-1 coverage varies so much by state

Federal law permits states to exclude drugs when used for weight loss. For covered outpatient drugs from participating manufacturers, Medicaid generally applies coverage rules to non-excluded medically accepted uses, subject to the statute and state authorization/formulary rules. A medically accepted indication can include specified compendial support as well as an FDA-approved use; it is not an automatic approval of every product, formulation, or claim.

You can read the exclusion in 42 U.S.C. § 1396r-8. The statute also recognizes specified compendial sources for medically accepted indications. State policy and the facts of an individual request still determine how those rules apply.

Some policy announcements cite budget pressure, but this review does not attribute every restriction or withdrawal to the same cause. An obesity-prevalence estimate is not a count of people eligible for, approved for, or treated with a GLP-1, and this tracker does not make that conversion.

A dated Philadelphia Inquirer report (April 10, 2026), citing the Pennsylvania Department of Human Services, said gross Medicaid GLP-1 spending rose from $233 million in 2022 to an estimated $1.3 billion in 2025, and its share of state Medicaid drug spending increased from 5% to 22%. These are attributed historical figures, not a finalized current net-cost measurement. This page does not use unscoped savings estimates as established outcomes.

Which states stopped covering Medicaid GLP-1s for weight loss in 2026?

Coverage policy changes include restrictions, withdrawals, reinstatements, and product-level updates. The dated observations below are not a complete September census, and counts from separate source releases should not be treated as one continuously verified series.

The change log distinguishes reported historical changes from current source checks and records a date and scope where established.

Sources: KFF and The RX Index historical snapshot; dated state-source links and row-level review dates appear in the policy table. Missouri’s January 9, 2025 start date is reported by its official document; adoption of the latest proposed revision remains unresolved.

The count series is historical context only. Keep the source date and definition attached whenever a figure is reused.

Source: KFF historical reports and The RX Index July 10, 2026 snapshot. The dates, source methods, and policy scopes differ; this is not a current national series.

Some sources describe budget concerns, but this page does not infer one shared cause for every change. Rhode Island’s notice is a scheduled October 1, 2026 exclusion for certain GLP-1 drugs prescribed solely for weight loss; it is not a completed change or a blanket diabetes-only restriction.

Does Medicaid cover Wegovy, Zepbound, Ozempic, or Saxenda?

Coverage depends on the prescribed product, formulation, indication, program, and applicable authorization rules. Ozempic and Mounjaro are not obesity-labeled products and should not be presented as routine obesity-coverage alternatives. Federal medically accepted-use rules are not limited to FDA-approved uses alone, but that does not guarantee an individual claim. The state table records source-backed obesity-policy details and their limits.

• Ozempic (semaglutide injection or tablets), Rybelsus (semaglutide tablets) and Mounjaro (tirzepatide injection) are not obesity-labeled products. Check the exact product, indication and Medicaid criteria; they should not be presented as routinely approved obesity alternatives to Wegovy or Zepbound.
• Wegovy (semaglutide injection and tablets): The current label includes adult weight-management and cardiovascular-risk-reduction indications for tablets as well as injection. The noncirrhotic MASH indication applies to injection for adults with F2–F3 fibrosis, not tablets.
• Zepbound (tirzepatide injection): Has separate adult obesity and obesity-associated obstructive sleep apnea indications. Neither indication guarantees state Medicaid coverage.
• Saxenda (liraglutide injection): An obesity-labeled product. North Carolina’s reinstatement includes Saxenda; see the state row for its preferred status and authorization requirements.
• Foundayo (orforglipron tablets): FDA approved on April 1, 2026 for adult obesity treatment; that approval does not establish a state Medicaid benefit.

Product-level rules vary by state and formulation. North Carolina’s cited reinstatement includes Wegovy, Zepbound, and Saxenda, with Wegovy preferred and the other two non-preferred. Missouri’s official obesity-specific document was read. It describes an existing pathway and reports a January 9, 2025 first-implementation date, but the revised document is headed “Criteria Proposal.” Adoption of the latest revision and its product preferences was not independently established. Michigan’s September common-formulary criteria require a highly restricted pathway; the state-specific source and limits are in the policy table. Do not infer a statewide BMI threshold or a Saxenda step requirement from another state’s rules.

What to do if your state’s Medicaid doesn’t cover GLP-1s for weight loss

“Not covered for weight loss” does not answer whether another indication, an individualized under-21 request, or a participating federal model applies. These are separate routes with separate rules, not guaranteed workarounds.

Sources: Federal Medicaid drug rules and EPSDT guidance, CMS’s BALANCE materials, and state notices cited in this article. These are general pathways, not individual coverage determinations.

For an individual request, check the applicable state or plan rules and ask the prescriber which indication and formulation are being requested. If a request is denied or coverage is terminated, read the notice for the applicable appeal deadline and any separate deadline to request continued benefits. Ask the program handling the request about expedited review when delay could seriously harm health. An appeal does not itself create an adult benefit that the state excludes.

Check your plan, not just your state: fee-for-service vs. managed care

The July national snapshot uses a fee-for-service baseline; the program scope for each newer finding is stated in its table row. A managed-care card does not necessarily mean the insurer chooses a separate drug list. A state may require a common formulary, set a coverage floor, or administer outpatient pharmacy outside the medical plan. Ask who controls the pharmacy benefit and which rules apply to the exact drug and indication. Changing plans is not a guaranteed way around a statewide exclusion. See our plan-by-plan managed-care tracker for separate research.

Before concluding that Medicaid will not cover a GLP-1, check these five things:

1. Who administers your benefits. Ask who administers your medical and pharmacy benefits. A company named on the card may be a health plan or a pharmacy administrator; confirm which rules control the requested drug.
2. What your plan’s formulary says. Call the number on the back of your card and ask whether the specific drug is on the preferred drug list for your specific indication.
3. Which indication your prescriber is using. Obesity, cardiovascular risk reduction, type 2 diabetes, and sleep apnea can get different answers from the same plan.
4. Whether the formulary changed recently. Plans update formularies regularly, so a “no” from six months ago may be out of date.
5. What prior authorization requires. Ask whether it is required for this drug and indication, and what documentation your prescriber needs.

This is educational information, not medical or legal advice. The Medicaid agency or health plan makes coverage determinations; the prescriber supplies the clinical information for the request.

Will the federal BALANCE Model change Medicaid GLP-1 coverage?

BALANCE is a voluntary CMS model; it does not automatically create coverage in every state. CMS allows state Medicaid agencies to join during the window beginning in May 2026 through January 1, 2027. The state RFA says a state becomes a participant upon signing a State Agreement. A press release, policy recommendation or budget instruction is therefore recorded separately from a verified agreement or an operational coverage start. Even participation does not guarantee approval of an individual prescription.

In this review, Indiana has a July 30 participation announcement; Maryland has a PDAB recommendation; and Virginia has evaluation authority in its enacted budget. These are different stages, not three confirmed live benefits. Other rows marked “Not verified” should not be interpreted as states declining the model.

Sources: CMS BALANCE Model, State RFA and Medicare GLP-1 Bridge, Information for Part D Plans; reviewed September 28, 2026.

The Bridge is separate from Medicaid and does not replace ordinary Part D coverage for other indications. CMS’s formulation-specific eligible-product list is Foundayo, Wegovy (injection and tablets), and Zepbound KwikPen only; it does not include every Zepbound formulation. For a full explainer on the Medicare GLP-1 Bridge, see the Medicare GLP-1 Bridge Tracker.

GLP-1 Medicaid coverage statistics: spending, prescriptions, and the data’s limits

KFF’s published CMS-data comparison reports higher Medicaid GLP-1 prescription counts and gross spending in 2024 than in 2019. The aggregate figures do not establish why any particular state changed its policy.

Source: KFF analysis of 2019 and 2024 CMS Medicaid drug data. Figures are gross of manufacturer rebates and are a dated benchmark, not September measurements. Prescription counts are not patient counts.

The spending figure is gross and does not reflect manufacturer rebates. The public data cannot separate use by indication, so it does not show how much was for diabetes, obesity, or another condition. These totals should not be used as a current net-cost estimate or as proof of a single policy driver.

Why this matters now

Coverage policy changes include restrictions, withdrawals, reinstatements, and product-level updates. The change log distinguishes announcements from effective policies and preserves the date and scope of each observation.

Limitations

We would rather you trust this page because we are clear about its edges than because we oversold it.

• Not a complete current census. The table includes 50 states and D.C., but some records remain unresolved or apply only to particular products or programs. No new national coverage total is calculated. A missing verification is not a finding of non-coverage or non-participation.
• Evidence has boundaries. A preferred listing is not an obesity approval. Some official sources are older, serve changing editions or have unresolved adoption/version questions. Those limits appear with the affected rows, including Missouri’s proposed revision and the Michigan, Tennessee and Virginia source-version issues.
• Different programs and indications can produce different answers. Fee-for-service and managed-care scope is recorded where established. Under-21 EPSDT and non-obesity indications are separate from the adult obesity-only comparison. A BALANCE announcement is not a confirmed active benefit.
• Historical figures stay historical. Prescription totals are not patient totals; spending is gross of rebates and does not separate indications. Earlier enrollment reach estimates remain withdrawn pending reproducible supporting data.

Frequently asked questions

How to cite this page

Sources

Official policy and drug-label sources

• U.S. Code 42 U.S.C. § 1396r-8 (Medicaid drug coverage and the weight-loss exclusion).
• CMS BALANCE Model.
• CMS BALANCE State Request for Applications, section 2.3.
• CMS Medicare GLP-1 Bridge — Information for Part D Plans.
• Medi-Cal Rx (California) GLP-1 coverage change notice.
• Pennsylvania DHS Medical Assistance Bulletin.
• NC Medicaid Reinstatement notice, Dec 19, 2025.
• Michigan MDHHS Letter L-25-73.
• University of Michigan Medical School Expert Q&A on Michigan’s GLP-1 limits.
• Utah Medicaid May 2026 Medicaid Information Bulletin 26-45 (fee-for-service coverage change effective June 30, 2026).
• MassHealth Corrected Pharmacy Facts 276 (obesity-only coverage change effective July 3, 2026).

National surveys and secondary analysis

These sources support dated national context and analysis; they are not a substitute for the current state policy cited in an individual row.

• KFF "Medicaid Coverage of and Spending on GLP-1s" (Jan 16, 2026).
• KFF "Medicaid Managed Care Tracker".
• KFF "What to Know About the BALANCE Model and the Medicare GLP-1 Bridge" (updated May 11, 2026).
• Milliman "The evolving landscape of anti-obesity medication coverage in Medicaid" (Mar 2026).
• Stateline "More states consider dropping GLP-1 weight loss drugs from Medicaid" (Apr 30, 2026).

This release documents only the state sources identified in its records. Review dates, source versions, and limitations are shown per row; the page-update date does not imply a full-jurisdiction verification.